Immunome (IMNM) Projected to Post Quarterly Earnings on Thursday

Immunome (NASDAQ:IMNM - Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Immunome to post earnings of ($0.72) per share and revenue of $3.16 million for the quarter.

Immunome (NASDAQ:IMNM - Get Free Report) last released its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). The company had revenue of $2.74 million during the quarter, compared to analysts' expectations of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunome Stock Down 5.5 %

Shares of NASDAQ:IMNM traded down $0.48 during trading on Friday, reaching $8.18. 4,323,434 shares of the company traded hands, compared to its average volume of 826,503. Immunome has a 1-year low of $8.17 and a 1-year high of $26.70. The firm has a market cap of $652.58 million, a P/E ratio of -1.01 and a beta of 1.93. The firm has a fifty day simple moving average of $9.76 and a 200 day simple moving average of $11.55.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Guggenheim lowered their target price on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday. Wedbush restated an "outperform" rating and issued a $33.00 target price on shares of Immunome in a report on Thursday. Stephens reissued an "overweight" rating and set a $30.00 target price on shares of Immunome in a research report on Thursday. Finally, Lifesci Capital initiated coverage on Immunome in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome presently has an average rating of "Buy" and an average target price of $25.50.

Remove Ads

Insider Activity

In other news, CEO Clay B. Siegall acquired 150,000 shares of the company's stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. This represents a 28.87 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.60% of the stock is owned by company insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.